NovaPoint Capital LLC Has $4.13 Million Stock Position in Johnson & Johnson $JNJ

NovaPoint Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 27,005 shares of the company’s stock after buying an additional 1,149 shares during the quarter. NovaPoint Capital LLC’s holdings in Johnson & Johnson were worth $4,125,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. AdvisorNet Financial Inc grew its holdings in Johnson & Johnson by 3.3% during the first quarter. AdvisorNet Financial Inc now owns 11,479 shares of the company’s stock valued at $1,904,000 after purchasing an additional 362 shares during the period. Spartan Planning & Wealth Management purchased a new stake in Johnson & Johnson in the first quarter worth $678,000. Doliver Advisors LP increased its position in Johnson & Johnson by 1.4% in the first quarter. Doliver Advisors LP now owns 14,191 shares of the company’s stock worth $2,353,000 after buying an additional 192 shares during the last quarter. Finally, Andrew Hill Investment Advisors Inc. increased its position in Johnson & Johnson by 129.0% in the first quarter. Andrew Hill Investment Advisors Inc. now owns 38,037 shares of the company’s stock worth $6,308,000 after buying an additional 21,428 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 1.1%

Shares of JNJ stock opened at $179.69 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The company has a market capitalization of $432.75 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 2.29 and a beta of 0.40. The business’s fifty day moving average is $174.41 and its 200 day moving average is $162.06.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the business posted $2.82 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s payout ratio is 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Royal Bank Of Canada raised their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.